Lungs News and Research

RSS

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

Chromogenic in situ hybridization can identify ALK rearrangement in lung cancer patients

A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

3 Aug 2011

Posttraumatic stress disorder linked to persistent fears of recurrent SAH

One-third of patients who have survived a life-threatening subarachnoid hemorrhage (SAH) have disabling symptoms of posttraumatic stress disorder (PTSD), reports a study in the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

3 Aug 2011

Double-lung transplant survivor stays busy since retirement

Fewer than half of lung transplant patients survive for five years. But nearly 14 years after receiving a double-lung transplant at Loyola University Medical Center, Damian Neuberger's lungs continue to function normally. He breathes easily while walking four or five miles a day.

3 Aug 2011

Study evaluates humor and laughter in patients with COPD

Having a sense of humor is associated with improved emotional functioning and an enhanced quality of life among patients with a chronic lung illness, but the actual act of laughing out loud can reduce lung function, at least in the short term, research suggests.

3 Aug 2011

New alternative to immunosuppressive treatment after kidney transplants without severe side effects

There is now a new alternative to immunosuppressive treatment after kidney transplants which comes without the usual severe side effects. The Medical University was significantly involved in the clinical development of the active ingredient Belatacept and a suitable preparation has now been given EU-wide authorisation.

3 Aug 2011

British scientists find seven new gene variants linked to prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.

3 Aug 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011

Scientists look to create blood platelets from stem cells to study genetics of blood clotting disorders

Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders. The study is funded by a $9 million grant from the National Institutes of Health (NIH) as part of a nationwide initiative to examine how genetic variations cause heart, lung and blood diseases.

2 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

2 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

NYU Langone receives NHLBI grant for comparative effectiveness ISCHEMIA Trial

NYU Langone Medical Center announced it has received an $84 million grant from the National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH), to study the comparative effectiveness of two initial management strategies for patients with coronary artery disease.

2 Aug 2011

Azithromycin may predispose cystic fibrosis patients to mycobacterial infection

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.

2 Aug 2011

Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM

Insmed Incorporated, a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease.

2 Aug 2011

Ursodeoxycholic acid could help prevent disturbances in heart's normal rhythm

A synthesised compound which is also found in bear bile could help prevent disturbances in the heart's normal rhythm, according to research published today in the journal Hepatology by a team from Imperial College London.

2 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Tunstall Healthcare launch new myclinic@home telehealth solution

myclinic@home is the latest in telehealth solutions, allowing remote patients to easily monitor their vital signs and manage a long term health condition in the comfort of their own home or a clinic setting, all supported by a health professional.

1 Aug 2011

Tips for obtaining life insurance after heart attack

Life Quotes, Inc. wants heart attack survivors to know that, while it may be tough to get a life insurance policy, it's not impossible. Heart disease is the #1 cause of death in America and many survivors are unaware of the life insurance options that may be open to them.

1 Aug 2011